[] Genzyme Corporate    [] Genzyme Websites   
In the treatment of osteoarthritis (OA) knee pain From a head-to-head trial of SYNVISC® (hylan G-F 20) vs. Hyalgan® (sodium hyaluronate).
SYNVISC provided superior pain relief1
Data shown for follow-up visits at 6 weeks, 3 months and 6 months. Mean age of patients was 67.2 years. Most had radiographically confirmed Kellgren-Lawrence grade III OA at baseline (SYNVISC 61%; Hyalgan 59%). Pain was measured on a 10-cm visual analog scale (VAS). Hyalgan is a registered trademark of Fidia S.P.A.
Study detail:
  • Prospective, observer-blinded, randomized, active-controlled trial
    of 392 patients with OA knee pain
  • 3 injections of SYNVISC vs.
    5 injections of Hyalgan
  • 26-week follow-up shown
  • Independently funded
SYNVISC is the #1
prescribed viscosupplement
in the United States2